Skip to main content
. 2024 May 28;15:1366035. doi: 10.3389/fphar.2024.1366035

FIGURE 4.

FIGURE 4

Funnel plots and subgroup analyses comparing the risks of MACE (A), myocardial reinfarction (B), and HF (C) with sacubitril–valsartan vs. ACEI/ARB in AMI patients after PPCI. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker. MACE, major adverse cardiac event; HF, heart failure.